MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

Search

Charles River Laboratories International Inc

Fermé

SecteurSoins de santé

219.06 0.06

Résumé

Variation du prix de l'action

24h

Actuel

Min

214.89

Max

227.8

Chiffres clés

By Trading Economics

Revenu

2.9M

56M

Ventes

-27M

1B

BPA

2.43

Marge bénéficiaire

5.529

Employés

18,700

EBITDA

-23M

198M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

-6.22% downside

Dividendes

By Dow Jones

Prochains Résultats

18 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1.5B

10B

Ouverture précédente

219

Clôture précédente

219.06

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Charles River Laboratories International Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 janv. 2026, 19:05 UTC

Principaux Mouvements du Marché

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13 janv. 2026, 23:41 UTC

Market Talk

Nikkei May Rise on Japan Election Hopes -- Market Talk

13 janv. 2026, 23:41 UTC

Market Talk

Global Equities Roundup: Market Talk

13 janv. 2026, 23:33 UTC

Market Talk

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13 janv. 2026, 23:13 UTC

Acquisitions, Fusions, Rachats

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13 janv. 2026, 23:10 UTC

Acquisitions, Fusions, Rachats

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13 janv. 2026, 23:03 UTC

Market Talk

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13 janv. 2026, 21:50 UTC

Acquisitions, Fusions, Rachats

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13 janv. 2026, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Basic Materials Roundup: Market Talk

13 janv. 2026, 21:20 UTC

Acquisitions, Fusions, Rachats

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13 janv. 2026, 21:20 UTC

Acquisitions, Fusions, Rachats

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13 janv. 2026, 21:20 UTC

Acquisitions, Fusions, Rachats

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13 janv. 2026, 21:15 UTC

Acquisitions, Fusions, Rachats

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13 janv. 2026, 21:08 UTC

Acquisitions, Fusions, Rachats

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13 janv. 2026, 20:39 UTC

Market Talk

Silver Settles at Another New High -- Market Talk

13 janv. 2026, 20:21 UTC

Market Talk

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13 janv. 2026, 20:17 UTC

Market Talk

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13 janv. 2026, 19:08 UTC

Acquisitions, Fusions, Rachats

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13 janv. 2026, 19:03 UTC

Résultats

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13 janv. 2026, 18:50 UTC

Résultats

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13 janv. 2026, 17:54 UTC

Market Talk

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13 janv. 2026, 17:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Global Equities Roundup: Market Talk

13 janv. 2026, 17:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13 janv. 2026, 17:49 UTC

Market Talk

Analysts Call For Potential Record Ethanol Output -- Market Talk

13 janv. 2026, 17:38 UTC

Market Talk

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13 janv. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

13 janv. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

13 janv. 2026, 17:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Basic Materials Roundup: Market Talk

13 janv. 2026, 17:19 UTC

Market Talk

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13 janv. 2026, 17:15 UTC

Market Talk

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Comparaison

Variation de prix

Charles River Laboratories International Inc prévision

Objectif de Prix

By TipRanks

-6.22% baisse

Prévisions sur 12 Mois

Moyen 202.1 USD  -6.22%

Haut 225 USD

Bas 170 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

12 ratings

8

Achat

4

Maintien

0

Vente

Score Technique

By Trading Central

117.16 / 144.77Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat